CO-CSG
11.6.2019 14:02:05 CEST | Business Wire | Press release
As new digital services are deployed to help communications service providers (CSPs) drive innovation, 5G core networks are becoming a necessity to enable true service differentiation. This need is quickly becoming realized, with two-thirds of organizations1 planning to deploy 5G by the end of next year. Not only will CSPs be expected to deliver a fully functional 5G network to meet end-user demand, but success will lie in the ability to provide innovative digital services and to fully monetize their 5G infrastructure investment.
Today, CSG announced the availability of its new 5G Dynamic Charging Function, designed to help CSPs optimize their strategy to not only deliver the value of 5G networks to customers, but also to optimize for sustainable growth in the digital economy. This new capability fulfils the roles of both the 5G Charging Function (CHF) and the Charging Gateway Function (CGF), providing offline and online mediation functionality in a single platform, while managing the complexity of all interfaces between the network and the BSS functions.
“The revenue potential resulting from the deployment of 5G networks should not be underestimated,” said Chad Dunavant, global head of product management, CSG. “But the next generation of business, from 5G to the Internet of Things, requires fundamentally new businesses models. The CSG 5G Dynamic Charging Function gives CSPs the foundation they need to capitalize and monetize on complete industry transformation.”
The CSG 5G Dynamic Charging solution enables operators to:
- Drive service differentiation : Facilitate the monetization of network slicing, enabling charging of tenants and differentiated services by charging in-slice and across slices.
- Minimize risk and disruption to existing systems : Provides a cost effective and efficient way for service providers to seize the 5G opportunity.
- Elastically scale : Automatically scale up to process large charging volumes and down when traffic subsides to optimize infrastructure costs.
- Deliver unparalleled capacity : Process millions of transactions a second with low cost infrastructure to deploy.
- Automate operations : With intelligent tools for diagnostics and troubleshooting.
- Support critical services : Single-digit latencies for real-time online charging transactions.
- Be vendor independent : Support network functions and OSS/BSS systems from any vendor. Eliminates network equipment provider siloes.
- Preserve existing investments : Seamlessly manage the integration of service-based interfaces to existing online charging system interfaces for faster time to market.
With hundreds of global installations, CSG has one of the most trusted mediation and transaction management solutions in the world. CSG supports mediation across any domain, across all mediation functions, for all deployment approaches. The solution captures and processes customer usage events of all kinds from any service delivery network for industry leaders in digital communications and media, financial services, logistics and government.
For more information on how to effectively monetize 5G, download the latest CSG whitepaper here .
About CSG
CSG (NASDAQ: CSGS) is a provider of software and services that help companies around the world monetize and digitally enable the customer experience. For more than 35 years, CSG has simplified the complexity of business, providing revenue management and digital monetization, payments, and customer engagement solutions to help our customers tackle any business challenge and thrive in an ever-changing marketplace.
Operating across more than 120 countries worldwide, CSG manages billions of critical customer interactions annually. CSG is the trusted partner driving digital innovation for hundreds of leading global brands, including Arrow Electronics, AT&T, Charter Communications, Comcast, DISH, Eastlink, Formula One, iflix, MTN and Telstra.
To learn more, visit our website at csgi.com and connect with us on LinkedIn , Twitter and Facebook .
1 Gartner 5G Adoption Survey, December 2018
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005208/en/
Contact:
Brad Jones Public Relations CSG +1 (303) 200-3001 brad.jones@csgi.com Liz Bauer Investor Relations CSG +1 (303) 804-4065 liz.bauer@csgi.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom